SAN JUAN, Puerto Rico -- The investigational antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab (Keytruda) demonstrated encouraging antitumor activity in patients with recurrent or metastatic cervical cancer, according to phase II...
Read more















